Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 14, 2025

Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy.

View Full Paper
Ask AI
Bookmark
Share

Authors

ZAZachary M. AviganJCJerrel L. CatlettSBSaoirse Bodnar

Discussion

Loading...

Member takes

Overview

Analysis reveals clonal hematopoiesis and inflammation influence hematologic toxicity and myeloid diseases post CAR-T therapy.

Key Points

  • Patients with grade ≥3 hematologic toxicity had poorer progression-free survival and overall survival rates, indicating high clinical risk.
  • Persistent inflammation and clonal hematopoiesis were linked to delayed recovery and development of secondary myeloid diseases in treated patients.
  • In-depth analysis conducted on 213 myeloma patients treated with BCMA-directed CAR-T therapy revealed these crucial associations.
  • Understanding how clonal dynamics affect BCMA CAR-T outcomes may refine therapeutic approaches and monitoring strategies.

Cite This Study

Avigan et al. (2025) studied this question.

synapsesocial.com/papers/689fc962e46e096235ce1ce5https://doi.org/10.1158/1078-0432.ccr-25-1587
View Full Paper
Ask AI
Bookmark
Share